EUCTR2009-012097-12-GB进行中（未招募）不适用
Phase II, open-label, multi-centre study of TP300 as a single agent as first line therapy in patients with advanced gastric cancer or gastroeosophageal junction adenocarcinoma. - TP103E
CHUGAI PHARMA EUROPE LIMITED0 个研究点目标入组 43 人开始时间: 2009年7月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient can be included in the study only if they meet all of the following criteria:
- •1.Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma (Siewart type II or III).
- •2.Male or female aged = 18 years.
- •3.ECOG performance status of 0 or 1.
- •4.Life expectancy of ³ 3 months.
- •5.Disease measurability, which can be assessed using the RECIST 1.1 criteria.
- •6.Adequate bone marrow function as defined by: absolute neutrophil count (ANC) of ³ 1.0 109/L, platelet count of ³ 100 109/L, and haemoglobin of ³ 9 g/dL.
- •7.Adequate liver function, as determined by:
- •Serum total bilirubin £ 1.5 (upper limit of normal [ULN]), aspartate amino transferase (AST) and alanine amino transferase (ALT) £ 2.5 ULN (£ 5 ULN if liver metastases); alkaline phosphatase (ALP) < 2.5 ULN (< 5 ULN if liver metastases).
- •Normal albumin.
- •There is no upper limit for ALP if elevation is due to bone metastases.
- •8.Adequate renal function shown by serum creatinine = 1.5 ULN.
- •9.Signed informed consent.
- •10.Ability to comply with protocol requirements (visits and assessment schedules) and willingness to allow blood sampling.
- •11.Females must be post-menopausal (12 months of amenorrhea), surgically sterile, or must agree to use a physical method of contraception. Oral or injectable contraceptive agents cannot be the sole method of contraception.
- •12.Male patients must be surgically sterile or agree to use a barrier method of contraception.
- •13.Female patients of child bearing potential must have a negative urine pregnancy test within the 7 days before study drug administration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from the study for any of the following reasons:
- •1.Patients with known (past or present) central nervous system (CNS) metastases.
- •2.Prior chemotherapy, radiotherapy (other than local palliative radiotherapy for bone pain), or immunotherapy within 28 days of first receiving study drug.
- •3.History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months before study treatment.
- •4.Prior toxicities from chemotherapy or radiotherapy that have not regressed to Grade £1 severity (NCI CTCAE version 3.0).
- •5.Prior corticosteroids as anti-cancer therapy within a minimum of 21 days of first receiving study drug.
- •6.No prior chemotherapy for (advanced, metastatic, or recurrent) gastric or gastro-oesophageal adenocarcinoma is allowed. Patients are allowed to have received prior neoadjuvant or adjuvant chemotherapy/chemo-radiation but at least 12 months should have elapsed since completion of neoadjuvant or adjuvant therapy.
- •7.Treatment with any investigational agent within 28 days of first receiving study drug.
- •8.Patients with active or uncontrolled infection. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding or any other medical condition that, in the opinion of the investigator, contraindicates the use of an investigational drug, or will impose excessive risk to the patient. Examples of such medical conditions include significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina pectoris) or severe obstructive pulmonary disease.
- •9.Major surgery within 28 days of first receiving study drug.
- •10.Pregnant or lactating women.
- •11.Altered mental status or psychiatric disorder that in the opinion of the investigator would preclude a valid patient informed consent.
- •12.Previous history of malignancy in the last 5 years except carcinoma in situ of the cervix or basal cell carcinoma of the skin.
研究者
相似试验
进行中（未招募）
不适用
The objective of the study is to understand if the association of the two drugs (trastuzumab and lapatinib), who both have as target the HER2 receptor with different mechanisms of action, can increase the chance of hitting the tumor compared to the association of trastuzumab to standard chemotherapy treatment, slowing or stopping the growth of cancer cells.HER2-positive metastatic breast cancer (MBC) refractory to anti HER2 therapiesMedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-005044-29-ITConsorzio Oncotech
进行中（未招募）
不适用
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumorscolorectal adenocarcinoma.metastatic pancreatic adenocarcinomamelanomaMedDRA version: 17.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000305-76-BEovartis Pharma AG91
进行中（未招募）
1 期
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumorscolorectal adenocarcinoma.metastatic pancreatic adenocarcinomamelanomaMedDRA version: 15.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: LLTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000305-76-FRovartis Pharma AG91
进行中（未招募）
不适用
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumorscolorectal adenocarcinoma.metastatic pancreatic adenocarcinomamelanomaMedDRA version: 14.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2012-000305-76-ITovartis Farma91
进行中（未招募）
不适用
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumorscolorectal adenocarcinoma.metastatic pancreatic adenocarcinomamelanomaMedDRA version: 16.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000305-76-DEovartis Pharma Services AG91